Related by context. All words. (Click for frequent words.) 56 CFR § #.# [007] 56 PS § 56 DC Code § 56 GLc 55 HRS § #-# [002] 55 § #.#.# [001] 55 § #.# [002] 55 CFR § #.# [006] 55 CFR § #.# [002] 55 § #A [001] 55 CA4 54 ORFs 54 USSG § 54 § #.# [003] 54 Supplementary Appendix 54 CFR § #.# [004] 54 ll.# 53 § #-# [001] 53 annexin 53 T#I [002] 53 § #-#-# [006] 53 NPM1 53 § #.#.# [002] 53 Rev. Proc 53 CFR § § 53 delipidation 53 antisense oligonucleotides 53 Ark. R. Civ 53 #.#-# [005] 52 § #A [002] 52 RC #.# [002] 52 #:#-# [002] 52 #.# subdivision [004] 52 NJRE 52 § #a [002] 52 § #-#.# [001] 52 USSG § #B#.# [002] 52 Reproduced Record RR 52 CFR § 52 MRS § 52 § #a [001] 52 Eur Urol 52 NJSA #:#-#.# [003] 52 hnRNP 52 Wis. Stat 52 § #L#.# 52 Repl. 52 Subsection c 52 RC #.# B [002] 52 prostanoid 52 s ection 52 NJSA 2A #A 52 ORS #B.# 51 RC #.# B [001] 51 LSA RS #:# [002] 51 section #.#.# 51 IC § #-# 51 FN1 51 NCGS § #A 51 NJSA #:#-# [002] 51 USC § #A 51 Pa.CSA § 51 #B#.# 51 CFR § #.# [005] 51 Rule #:#-# [001] 51 NCGS § 51 USC § #u 51 subsection c 51 NJSA 2A :# 51 CFR § #.# [001] 51 Amending Directive 51 CFR § § #.# [001] 51 La. RS #:# [003] 51 Ark. Sup 51 #.# subd [004] 51 Pa.CS § 51 VSA § 51 ERISA § 51 § #E 51 LSA RS 51 subpart 51 La. RS #:# [002] 51 CFR #.# [002] 51 § #-#-# [002] 51 USC § #a [001] 51 subsection f 51 CFR #.# c 51 § #-#.# [002] 51 Supplementary Table 51 NJSA #:#-# [004] 51 inventorship 51 Supp. 51 Aplt 51 § #C#.# 51 Section #.#.# [001] 50 Pricing Supplement 50 Section #.# [001] 50 adjuvant systemic 50 § #-#-# [008] 50 Judgments § 50 § #A [003] 50 subsection d 50 LSA CCP art 50 COLD PCR 50 tumorigenicity 50 § #-#-# [004] 50 Pa. Code § 50 RSMo 50 USCS § 50 phospholipase 50 Id. § 50 § § #-#-# [001] 50 NJAC 6A 50 GL c 50 κ 50 § #B#.# [002] 50 PAJA 50 Tr. 50 PDE# inhibitors 50 NJSA 2C :5 50 Code § #.#-# [001] 50 Ann Emerg Med 50 § #-#-# [001] 50 OCGA § #-#-# [004] 50 § 7A 50 CFR § #.# [008] 50 Suppl. 50 Restatement § 50 Zevalin consolidation 50 § #-#.# [003] 50 La. Code Civ 50 Sentencing Guidelines Manual 49 autosomal 49 NOD mouse 49 #a subdivision 49 #A#.# 49 Younger abstention 49 CFR § #.# [003] 49 CrR #.# 49 Idaho Code § 49 cmt 49 OvaRex MAb 49 Okla. Stat 49 mITT population 49 ARS § 49 immunostaining 49 § #-#-# [003] 49 Bankruptcy Code § 49 Rule #:#-# [002] 49 J Clin Oncol 49 CFR § § #.# [002] 49 interleukin IL 49 ATL# [001] 49 LSA RS #:# [001] 49 Pa.RAP 49 RCW #.#A.# 49 b Vernon Supp 49 RC #.# F 49 SOCS3 49 CFR #.# [005] 49 USC § #b [002] 49 § #.# subd [005] 49 NJSA #:#-# [001] 49 immunohistochemical 49 Evid.R. 49 anti CD# antibodies 49 NJSA #:# [002] 49 mimetic peptide 49 § #a [003] 49 pharmacogenetic testing 49 La. RS #:# [001] 49 homocysteine assay 49 § #.# [006] 49 mineralocorticoid receptor 49 Interferon alfa 49 Psychodynamic 49 hierarchical clustering 49 NJAC #:#-#.# 49 Wyo. Stat 49 USC § #f 49 Mitotic 49 RSA #:# [001] 49 Nat Biotechnol 49 unpatentable 49 § #.# [004] 49 v. Teleflex Inc. 49 OCGA § #-#-#.# 49 NJSA #A 49 murine monoclonal antibody 48 ORS #.# [001] 48 pyrimidine 48 § #A.# 48 Practice Direction 48 #.# subds [001] 48 reexamination proceeding 48 See Restatement Second 48 Minn. R. Civ 48 USC § #c 48 :9 48 judicial estoppel 48 Nat Genet 48 isomerase 48 § #-# [004] 48 CFR #.# d 48 footnote omitted 48 Vernon Supp 48 OCGA § 48 #K#.# 48 #.# subdivision [002] 48 histone H3 lysine 48 Therasense 48 pmol 48 uPA 48 See USSG § #B#.# 48 XmAb# 48 methyltransferase 48 Minn. R. Crim 48 Mol Cell 48 NYCRR § 48 § #-#-#.# 48 Rev. Rul 48 See USSG 48 DTR #.#.# b 48 USSG § #A#.# b 48 cTnI 48 e xcept 48 Histologic 48 cytidine 48 Arch Dermatol 48 myeloproliferative diseases 48 constitutively active 48 comparative genomic hybridization 48 KRAS mutation 48 prucalopride 48 suppl. 48 NJSA 2C :2 48 ddRNAi 48 Suppl 48 HRS § 48 footnotes omitted 48 App'x 48 quantitative PCR qPCR 48 Rent Stabilization Code 48 § #c 48 NJSA #:#-#.# [001] 48 dorsal root ganglion 48 KSA #-# b 48 RNA seq 48 #.# 5T 48 posterior cingulate 48 Fam. Code § 48 mutational analysis 48 Spreigl evidence 48 La.RS #:# [003] 48 MGd 48 RCr 48 Sentencing Guidelines Manual USSG 48 USCA § 48 Hofsheier 48 FFDCA 48 FASEB J. 48 NR2B subunit 48 J Biol Chem 48 subparagraphs 48 Arch Neurol 48 Am J Epidemiol 48 patentable invention 47 § #A#.# 47 J Clin Psychiatry 47 subparts 47 USC § #a [003] 47 ORS #A.# 47 § 7B 47 plasma kallikrein 47 Ariad patent 47 #.#A [001] 47 #.# subd [006] 47 OCGA § #-#-# [007] 47 KSA #-# d 47 GeneCards R 47 dinucleotide 47 IRCP 47 Hatch Waxman Amendments 47 TCA § #-#-# [003] 47 cytochrome c oxidase 47 2d Dept 47 IC § 47 supra § 47 Arch Intern Med 47 Cancer Res 47 La.Civ.Code art 47 enantiomer 47 NJSA #A :# 47 Cabilly patent 47 colorectal liver metastases 47 Clinical Outcome 47 cathepsin B 47 AS #.#.# 47 Dkt. No. 47 Maj. Op 47 § #G#.# 47 BPAI 47 Tuschl III 47 histone deacetylase HDAC 47 subsection h 47 CFR Pt 47 EMBO J. 47 CALCRIM Nos. 47 KRS #.# [003] 47 Kraepelin 47 somatosensory evoked potentials 47 NJSA #:#-# [003] 47 CALCRIM No. 47 #A.# [005] 47 + enantiomer 47 ORS #.# [002] 47 § #-# [002] 47 N glycan 47 SEC Rule #b 47 #d# [001] 47 Lenocta 47 No. RE# [001] 47 § #.#-# [004] 47 KSR Int'l Co. 47 Evid. Code § 47 IRTPA 47 USC § #a b 47 Florida Statutes 47 #-#.# [016] 47 NJSA 47 Ann Intern Med 47 Notice #-# [001] 47 G#DT 47 serovar 47 overbreadth doctrine 47 LPS induced 47 Tenn. R. Civ 47 Phosphorylation 47 myeloproliferative disorders 47 KRS #A.# [002] 47 epigenetic therapies 47 USSG § #K#.# b 47 Slip op 47 Degenerative Disc Disease 47 CrR 47 lipid biosynthesis 47 Crim.R. 47 VEGFR1 47 #.# subdivision [003] 47 Colo. Sess 47 § #b [001] 47 NJSA #:# [001] 47 Minn. Stat 47 State ex rel 47 CysDisplay 47 ResQNet 47 suppl 47 dispositive motions 47 overbreadth 47 myeloproliferative 47 Accelerated Approval 47 Colorado Revised Statutes 47 p# biomarker 47 People v. Doganiere 47 Fed.R.Civ.P. 47 BACcel 47 § #.# b 47 dipeptidyl peptidase IV 47 cathepsin 47 metaplasia 47 Income Tax Regs 47 allergic airway inflammation 47 aCGH 47 biologic plausibility 47 homology 47 Environ Health Perspect 47 OCGA § #-#-# [001] 47 Eminent Domain Procedure 46 IFN α 46 III.#.# 46 See ARS § 46 Due Process Clause 46 immunofluorescence staining 46 RS #:# [002] 46 La.RS #:# [002] 46 phage display technology 46 OCGA § #-#-# [006] 46 § #A b 46 racemate 46 protein tyrosine phosphatase 46 somatostatin analogue 46 § #G#.# b 46 S ection 46 Torts § 46 Ohio Adm.Code #-#-# 46 § #:# [001] 46 OCGA § #-#-# [008] 46 subsection b 46 #.#-# b [001] 46 Nat Med 46 section #-#-# [003] 46 PrevOnco 46 Va. Code § 46 § #.# [001] 46 #:#-# [033] 46 Fig. 1D 46 Free Full Text 46 INA § 46 bioactive peptide 46 General Statutes § 46 Subsection b 46 8 CFR § 46 § § #.# [002] 46 hypothalamic pituitary 46 § § #-# [001] 46 tissue microarray 46 Illumina GoldenGate 46 Odyssey Thera 46 M1 muscarinic 46 Tuschl 46 CODE § 46 CEQA Guidelines 46 § #E#.# 46 La.Code Crim.P. art 46 CRCP 46 ENMD # 46 Evidence Code 46 Spiegelmers 46 NanoCrystal Technology 46 § #K#.# 46 radiographic evaluation 46 CFR #.# [006] 46 CFR #.# [007] 46 MNTX 46 See TCA § 46 ,#,# [002] 46 OCGA § #-#-# [002] 46 #.#-# [006] 46 Appellant Brief 46 pathophysiologic 46 § 46 methotrexate therapy 46 Thromb Haemost 46 EDPL 46 caselaw 46 J Neurosurg 46 rs# [004] 46 ClinicalTrials.gov 46 BXT # 46 PFGE 46 Louisiana Revised Statutes 46 CD# [004] 46 null null 46 eculizumab therapy 46 CFR pt 46 p rior 46 Contracts § 46 reh'g 46 Supplemental Figure 46 patentably distinct 46 subsections b 46 gross disproportionality 46 dSLIM 46 Compl 46 thorough QT 46 VIOXX Product 46 Tumor Response 46 Supplementary Figs 46 USSG § #L#.# 46 Obes Res 46 syngeneic 46 Civ. Code § 46 cytoreductive nephrectomy 46 § #K#.# b 46 § #D#.# 46 rhIGFBP 3 46 #CFR 46 extra articular 46 KRS #A.# [001] 46 #,#-# [008] 46 HRS § #-# [001] 46 See id 46 SLUSA 46 GlycoGenesys 46 Subsections 46 § #-# [003] 46 hamartomas 46 END FOOTNOTE FOOTNOTE 46 NCGS 46 R. #:#-# 46 subparagraph B 46 MSc Qualified Person 46 Schizophrenia Bulletin 46 La.RS #:# [001] 46 interferon γ 46 CFR #.# [001] 45 USSG § #A#.# 45 AEDPA 45 § § 45 KRS #.# [002] 45 multivariate Cox 45 downregulation 45 hip resurfacing arthroplasty 45 Evid 45 Exh 45 § #-#-# b [003] 45 Enabling Clause 45 χ 45 Kunekt Corporation 45 USC § #e 45 Def. s 45 HCV genotyping 45 § #-#-# [007] 45 Am J Pathol 45 chromosome #q#.# [001] 45 Kidney Int 45 wedge Hole TC# 45 Cabilly 45 Am J Cardiol 45 chemically modified siRNA 45 J Clin Invest 45 dispositional order 45 § #-#-# c [001] 45 Hr'g Tr 45 '# patent ll.# 45 NJSA #:# C 45 RECALL VAX TM 45 Section #-#-# [006] 45 Rule #:#-# b 45 IIRIRA 45 #-#-#.# [002] 45 MPEP § 45 p.# [001] 45 KSA #-# [001] 45 Ii protein 45 JAK inhibitors 45 USC § #t 45 gefitinib Iressa 45 Immunostimulatory 45 Non GAAP reconciliations 45 #:#-# [027] 45 PDZ domain 45 T SPOT.TB 45 Prof. Code § 45 Proximate cause 45 cytological 45 :4 45 antiangiogenic agent 45 CFR #.# [008] 45 RCW #A.#.# [002] 45 EP# [001] 45 #:#-# [028] 45 USSG § #G#.# 45 MorphoSys proprietary 45 IL 1ß 45 USSG § #C#.# 45 EP# [005] 45 factorial 45 PIX# trial 45 Missouri Revised Statutes 45 section #A.# [002] 45 Arkansas Code Annotated 45 recurrent glioma 45 antagomirs 45 § #B 45 f ailure 45 p# INK4a 45 Section #B#.# 45 G# [003] 45 § #B#.# b 45 Resp't 45 para. 45 kidney urologic 45 pathologic diagnosis 45 preclusion 45 § #.# d 45 Gen. Stat 45 polycystin 45 VNTR 45 rebuttable presumptions 45 multiplanar 45 NJSA 2C :# 2a 45 Probate Code 45 roving wiretap provision 45 USSG 45 antigen identification 45 psychometrically sound 45 USC #d 45 Cell Biol 45 miRNA therapeutics 45 nonfinal 45 #:# [013] 45 Oregon Revised Statutes 45 Ind. Code § 45 microdeletions 45 quasispecies 45 END FOOTNOTE 45 § § #-# [002] 45 Liability Lawsuits 45 biliary tract cancer 45 TCA § 45 splenocytes 45 meniscectomy 45 Br J Dermatol 45 Int J Epidemiol 45 mGluRs 45 Premarket Notification 45 J Natl Cancer Inst 45 Osteoporos Int 45 Subsection d 45 PS § § 45 Fig. 2a 45 #a #a [002] 45 Annexin 45 USSG § #B#.# b 45 vidofludimus 45 Docket Number 45 CRp 45 Mechanistic 45 Third Amended Complaint 45 KRS #.# [001] 45 Proposed Rule 45 #-# CB 45 intraventricular 45 Rule #:#-# e 45 WpHG mit dem Ziel 45 OCGA § #-#-# [005] 45 Pen. Code § § 45 Gov't Code § 45 NJSA #A #A 45 2d ed 45 SNP Genotyping 45 § #L#.# b 45 IRC § 45 claim preclusion 45 Defendant asserts 45 obviousness rejection 45 nonprecedential 45 haematologic 45 USC § #a c 45 enantiomers 45 fibrotic disease 45 k Premarket Notification 44 mutant alleles 44 Appendix B 44 glycosylation profile 44 section #-#-# [002] 44 unpatentable abstract idea 44 TMPRSS2 ERG fusion 44 BIIR 44 NYCHRL 44 n othing 44 Nanobodies 44 #:#-# [018] 44 u pon 44 osteoinductive 44 Apolipoprotein 44 De Varon 44 § #-#-# c [002] 44 #A.# [002] 44 lysophosphatidic acid LPA 44 Docket Entry No. 44 Tennessee Code Annotated 44 endonuclease 44 Fla. 3d DCA 44 HRCT 44 CrossRef Medline 44 enclosed herewith 44 2C :# 44 quotation omitted 44 STAT5 44 inotropic 44 Arizona Revised Statutes 44 CALCRIM 44 B.1 44 A#V 44 nondischargeability 44 section #-#-# [001] 44 aortic root replacement 44 Hawaii Revised Statutes 44 Xiu Xia Lin 44 NDCC § 44 Defendant argues 44 CPLR § 44 People v. Gardeley 44 integrin alpha 44 Rooker Feldman 44 D Dimer 44 epigenomics 44 #.# subds [003] 44 SELDI 44 #.#-# b [002] 44 MC# [001] 44 Evid. Code § § 44 Lipid Sciences 44 Code Civ 44 urethroplasty 44 J Clin Endocrinol Metab 44 Î ² 44 Eur Respir J 44 RCW #.#.# [002] 44 reexamination proceedings 44 denervation 44 appellants contend 44 Subparagraph 44 OS# § 44 Dent Res 44 Clin Cancer 44 MRC# [001] 44 histologic findings 44 plainly erroneous 44 lenity 44 subclause 44 placebo controlled multicenter 44 #a #a [001] 44 #.#-# [017] 44 #b c 44 Neurosci 44 Accelerated Examination 44 fusion enhancers 44 #-#-#.# [004] 44 FSIA 44 UCB Pharma SA 44 Clin Endocrinol 44 VerifyNow P#Y# 44 AFI #-# 44 USC § #a [002] 44 CS § 44 linear interpolation 44 PMID # [002] 44 HuCAL GOLD R 44 FASB ASC 44 USSG § #D#.# 44 #:#-# [029] 44 Reply Brief 44 Respondent contends 44 Louisiana Revised Statute 44 § #.# subd [002] 44 hexose 44 La.RS 44 Symadex 44 enzastaurin 44 PATENT 44 Interrogatory No. 44 Supplementary Material 44 n.5 44 Xanafide 44 La.Code Civ.P. art 44 § #.#-# [002] 44 fig. S1 44 #.# subd [003] 44 TRIPs Agreement 44 ORCP 44 Implementing Regulations 44 #.#A [005] 44 KAR #:# 44 RCr #.# 44 #:#-# [014] 44 Rule #-# 44 Defendant contends 44 ZapMedia applied 44 Psychiatry Res 44 subchapter 44 Dynabeads 44 Centralized Procedure 44 MoxDuo 44 Code § #-# [003] 44 equitable mootness 44 END FOOTNOTE * 44 People v. Waidla 44 Appellants argue 44 Premarket Approval 44 LDTs 44 #.#-# [020] 44 Section #-#-# [004] 44 Fig. 1d 44 xsl template 44 #.# [042] 44 nonobvious 44 CALJIC 44 Res judicata 44 ITEPA 44 IC § § 44 AIPLA 44 COMAR 44 Methylnaltrexone 44 FASB ASC Topic 44 clinicopathological features 44 patentee 44 eukaryotic initiation factor 44 dose escalation clinical 44 § #.# Vernon 44 NYCRR #.# [002] 44 Restatement Second 44 facially invalid 44 Elias Zacarias 44 Collateral estoppel 44 AST ALT 44 irreducible complexity 44 IP5 44 N Engl J 44 IRC § § 44 #.# RSMo 44 haematopoietic 44 § #-#-# [005] 44 jurisdictional prerequisite 44 papillary renal cell carcinoma 44 Acad Emerg Med 44 RECALL VAX 44 pari materia 44 Rehearing En Banc 43 § #B#.# [001] 43 RCEs 43 Pharmexa 43 noninfringement 43 Synapt HDMS 43 KSA #-# [002] 43 NEUVENGE 43 Dr. Siegall 43 n.8 43 creates rebuttable presumption 43 logistic regressions 43 Equitable tolling 43 Expedited Review 43 transmembrane protein 43 Betaseron ® 43 La. RS #:#.# 43 CFR Parts 43 trastuzumab DM1 T DM1 43 generalizability 43 Section #-#-# [005] 43 AlloMap 43 See INA § 43 Ariad 43 integrable 43 firearm Pen. Code § 43 OCGA § #-#-# [003] 43 pelvic lymph node dissection 43 UKIPO 43 ORC § 43 § #-#-# b [001] 43 brivaracetam 43 DispersinB ® 43 Tafas v. Doll 43 lumbar interbody fusion 43 Ohio Adm.Code 43 Inequitable conduct 43 BAPCPA 43 Microwave Ablation System 43 Smooth Muscle 43 J Biol 43 s uch 43 costimulatory molecules 43 JAK2 mutation 43 Penal Code Sec 43 § #D#.# b 43 La.RS #:#.# [001] 43 Br J Radiol 43 Eq. 43 Rosenkrantz supra 43 J Pediatr 43 Neuroimage 43 USC § #b [001] 43 Kentucky Revised Statutes 43 People v. Carmony 43 MR Civ 43 Appellate Division affirmed 43 pulse amplitude 43 p laintiff 43 Section #.# RSMo 43 Issued Patent 43 Transcript Docket 43 mem. op 43 www.systemc.org 43 laparoscopic radical nephrectomy 43 J Clin Epidemiol 43 array CGH 43 Sanger sequencing 43 Celotex Corp. v. Catrett 43 ARS § #-# [002] 43 Appellant asserts 43 § § #-# [003] 43 TRUS 43 Reply Br 43 Exercising jurisdiction 43 Ectopic 43 i fa 43 USC § 43 WAC #-#-# 43 Res.# 43 CALJIC No. #.# 43 '# patents 43 Minn. R. Evid 43 n.1 43 ILCS #/#-# [001] 43 IGF 1R inhibitor 43 ADAAA 43 See USSG § #A#.# 43 interobserver reliability 43 NJSA 2C :# 3a 43 CD8 ^ sup 43 Nat Neurosci 43 hepatocellular carcinomas 43 AFLP 43 certif 43 experimental autoimmune encephalomyelitis 43 DP4 43 putative biomarkers 43 Clin Psychol Rev 43 Eur Heart 43 transthoracic 43 somatostatin analogues 43 Arizona Revised Statute 43 IVMD 43 STELA 43 Gall v. 43 Surgical resection 43 novel emulsion formulation 43 striatal dopamine 43 inter partes reexamination 43 subds 43 requestor petitioner 43 Civ.R. 43 Analytical Reasoning 43 affd 43 Interrogatory 43 5th DCA 43 n.# [001] 43 id. 43 Ark. R. Crim 43 op. 43 Phase IIB 43 lodestar method 43 NDCC ch 43 phosphatidylinositol 43 C.# 43 NOPR 43 Rooker Feldman doctrine 43 TLIF 43 Ex parte Young 43 Option IVC Filter 43 internal citation omitted 43 jurisdictional defect 43 Doc. No. 43 Geier supra 43 BioSilicon 43 P. #a 43 VCRT 43 Docket Nos. 43 RA# [003] 43 Fig. 3b 43 Phase Ib study 43 Fla. 2d DCA 43 RGD peptides 43 Figure 1A 43 Internal Revenue Code § 43 thoracoscopic lobectomy 43 IV.#.# 43 hematopoietic cancers 43 Y# [004] 43 syndromal 43 J Affect Disord 43 PharmaStem 43 Reasonable suspicion 43 syntaxin 43 ganaxolone 43 Code § #-# [001] 43 b#x# http:/#.#.#.#/fls.geo/PH #x# #.hyahrtzeit 43 #a #a [003] 43 Exs 43 invariance 43 J Exp Med 43 patented invention 43 CT urography 43 sua sponte dismissal 43 :7 43 basolateral 43 w henever 43 J Immunol 43 Appendices 43 Saffran patent 43 KRS #.#-# 43 § #.#-# [001] 43 #:#-# [037] 43 transvaginal sonography 43 gastric carcinoma 43 Criminal Procedure Law 43 bioequivalency 43 subparagraph 43 NJSA 2C :# 43 Chp 43 CPLR 43 Act Pub. L. 43 Hypertens 43 n.4 43 confirmatory Phase 43 wavelet transform 43 section #.# 43 Protein Structure